BUENOS AIRES — The idea of a vaccine for lung cancer sounds absurd at first. Lung cancer isn’t the flu, after all. But, after a 19-year quest by researchers in Argentina and Cuba, such a medicine is now a reality. The story of the vaccine begins in 1994, when a group of Argentine scientists who dreamed of creating a cancer vaccine met with a group of Cuban scientists who had an idea of how to make one. And it reaches its finale on July 1, when a drug called Vaxira (Racotumomab) goes on sale in Argentina. Developed by ID+i, an Argentine consortium of universities, government ministries, and Grupo Insud, a local pharmaceutical conglomerate, along with Cuba’s Molecular Immunology Center (CIM, in Spanish), the vaccine required $100 million of investment, Dr. Hugo Sigman, Grupo Insud’s CEO and the founder of ID+i, says. Besides Argentina, the drug has also already been approved in Cuba and has been licensed to 25 countries in the Americas and Asia, from Brazil to Cambodia. One of the more head-turning aspects of the drug is its classification as a vaccine. It is not a vaccine in the traditional sense of a preventative shot given to kids, but… Read full this story
- Therapeutic Vaccines Market 2016: Global Industry Review, Research, Statistics, and Growth to 2021
- The market for anti-cancer drugs will usher in a high growth
- New Study Reveals How Aluminium Promotes Cancer Growth
- A vaccine for the prevention of cervical cancer?
- Minister 'looking seriously' at compulsory vaccines
- Natural Supplements vs. Pharmaceutical Drugs: The Politics of Surviving Cancer
- Medical science: Spain's latest 'Eureka' moments
- Big Pharma’s worst nightmare
- Fact or Fiction -Sex Q Answered
- 'Flu is still dangerous' say couple who lost son
A 'vaccine' for lung cancer? have 277 words, post on www.zdnet.com at June 27, 2013. This is cached page on Drudgereport. If you want remove this page, please contact us.